Life Sciences Tools and Services
Company Overview of SomaLogic, Inc.
SomaLogic, Inc. operates as a life science tools and clinical diagnostics company. It offers Slow Off-rate Modified Aptamer (SOMAmer) technology to develop and commercialize proteomic life sciences research tools for the research community; and discover, develop, and commercialize life science research tools and breakthrough clinical diagnostic products that transform healthcare. The company also provides SOMAscan assay, a protein biomarker discovery tool for the life sciences community; SOMAmer reagents, which enable a host of life science applications, including quantitative measurement of individual proteins, histochemistry of frozen tissue samples, flow cytometry, and affinity purificati...
2945 Wilderness Place
Boulder, CO 80301
Founded in 1999
Key Executives for SomaLogic, Inc.
Chief Executive Officer and Director
Founder and Chairman of the Board
Chief Medical Officer Emertius
Compensation as of Fiscal Year 2014.
SomaLogic, Inc. Key Developments
SomaLogic, Inc. Announces Extension of Multi-Year Collaboration Agreement with Novartis Institutes for BioMedical Research
Oct 20 14
SomaLogic, Inc. announced that Novartis has extended its multi-year research agreement for the development and application of SomaLogic's unique proteomics technology to Novartis' drug discovery and development efforts. Novartis will also take an equity position in SomaLogic under the agreement extension. Under the previous collaboration agreement, scientists at the Novartis Institutes for BioMedical Research and SomaLogic worked together to build an enhanced proprietary version of SomaLogic's SOMAscan proteomics assay for NIBR. The collaboration also included development of specific novel SOMAmer binding reagents for multiple preclinical and clinical applications in NIBR's research and development portfolio. The collaboration extension announced will enhance and expand these efforts in addition to the equity investment in SomaLogic. Other specific terms of the agreement were not disclosed. Compared to other current proteomic technologies, SomaLogic's offerings provide researchers with unprecedented power for protein biomarker discovery, diagnostics development, and pharmaceutical discovery and development. SOMAmer reagents, which are at the center of SomaLogic's proteomics platform, are a new class of superior protein-binding reagents that combine the best properties of both monoclonal antibodies and traditional aptamers. They have wide applicability in many current preclinical and clinical analytical assays, including quantitative high-content screening, targeted panels, flow cytometry, histochemistry, functional assays, and biophysical methods. SomaLogic's commercially available SOMAscan assay, which incorporates 1,129 different SOMAmer reagents, can efficiently, accurately, and rapidly measure proteins across a wide range of concentrations in small volumes of multiple biological sample types.
National Institutes of Health Center for Human Immunology, Autoimmunity and Inflammation to Use SomaLogic, Inc.'s SOMAscan(TM) Proteomics Assay
Oct 13 14
SomaLogic, Inc. announced that the National Institutes of Health (NIH) Center for Human Immunology, Autoimmunity and Inflammation (CHI) will use the SOMAscan(TM) proteomics assay for research with collaborators across the NIH. It is expected that the SOMAscan assay will be installed and fully functional at CHI by the beginning of 2015. Compared to other current proteomic technologies, SomaLogic's offerings provide researchers with unprecedented power for protein biomarker discovery, diagnostics development, and pharmaceutical discovery and development. SOMAmer(R) (Slow Off-rate Modified Aptamer) reagents, which are at the center of SomaLogic's proteomics platform, are a new class of superior protein-binding reagents that combine the best properties of both monoclonal antibodies and traditional aptamers. The SOMAscan assay, which incorporates 1,129 different SOMAmer reagents, can efficiently, accurately, and rapidly measure proteins across a wide range of concentrations in small volumes of multiple biological sample types. SomaLogic is continuing to expand access to its SOMAscan assay through its placement in leading academic research centers. Current sites, in addition to CHI, include Massachusetts General Hospital and the University of Pennsylvania, with several more expected to be announced in the coming weeks.
Children's Hospital Colorado and SomaLogic, Inc. Announce Collaboration to Develop Novel Diagnostic Tests for Childhood Diseases
Oct 8 14
Children's Hospital Colorado and SomaLogic, Inc. announced that they have entered into a collaborative agreement to discover protein biomarkers and use those biomarkers to develop laboratory tests to improve the diagnosis and management of childhood diseases. The discovery and development work will be done using SomaLogic's novel proteomics SOMAscan(TM) assay, which can measure more than a thousand proteins in a small amount of blood or other biological samples. This innovative collaboration is being entered into as a result of successful initial exploratory research done by the two organizations. The research team will be led by Robin Deterding, M.D., Director of the Breathing Institute at Children's Colorado, Professor of Pulmonary Medicine in the Department of Pediatrics at the University of Colorado School of Medicine, and Chair of the North American Children's Interstitial and Diffuse Lung Disease Research Network (CHILDRN). Deterding is an international expert in the care of children with rare diffuse lung disease. Under the agreement, researchers at Children's Colorado and SomaLogic will work together to widely analyze the proteins from blood samples obtained from children suffering from disease. They will then select those proteins, or biomarkers, whose change in concentration is correlated with disease (and its severity) to serve as a basis for developing in-house diagnostic tests for future clinical use. These tests will rely on SomaLogic's technology, which can be scaled to measure from thousands of proteins for discovery of biomarkers to only a few selected proteins for diagnostic purposes.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|